Incidence and Management of Restenosis After Treatment of Unprotected Left Main Disease With Second-Generation Drug-Eluting Stents (from Failure in Left Main Study With 2nd Generation Stents–Cardiogroup III Study)

MLA

Claudio Moretti, et al. “Incidence and Management of Restenosis After Treatment of Unprotected Left Main Disease With Second-Generation Drug-Eluting Stents (from Failure in Left Main Study With 2nd Generation Stents–Cardiogroup III Study).” The American Journal of Cardiology, vol. 119, Apr. 2017, pp. 978–82. EBSCOhost, https://doi.org/10.1016/j.amjcard.2016.12.005.

APA

Claudio Moretti, Alaide Chieffo, Maurizio D’Amico, Javier Escaned, Giuseppe Biondi-Zoccai, Giacomo Boccuzzi, Roberto di Summa, Ferdinando Varbella, Fabrizio D’Ascenzo, Fabrizio Ugo, Roberto Garbo, Marco Pavani, Sara Rettegno, Antonio Colombo, Fiorenzo Gaita, Federico Conrotto, Hyroishi Kawamoto, Enrico Cerrato, Antonio Montefusco, & Pierluigi Omedè. (2017). Incidence and Management of Restenosis After Treatment of Unprotected Left Main Disease With Second-Generation Drug-Eluting Stents (from Failure in Left Main Study With 2nd Generation Stents–Cardiogroup III Study). The American Journal of Cardiology, 119, 978–982. https://doi.org/10.1016/j.amjcard.2016.12.005

Chicago

Claudio Moretti, Alaide Chieffo, Maurizio D’Amico, Javier Escaned, Giuseppe Biondi-Zoccai, Giacomo Boccuzzi, Roberto di Summa, et al. 2017. “Incidence and Management of Restenosis After Treatment of Unprotected Left Main Disease With Second-Generation Drug-Eluting Stents (from Failure in Left Main Study With 2nd Generation Stents–Cardiogroup III Study).” The American Journal of Cardiology 119 (April): 978–82. doi:10.1016/j.amjcard.2016.12.005.